| Nov 15 |
ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
|
| Nov 14 |
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
|
| Sep 17 |
ArriVent BioPharma: Bringing A Novel Cancer Drug From China
|
| Sep 9 |
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
|
| Sep 6 |
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate
|
| Aug 19 |
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
|
| Aug 14 |
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
|
| Aug 12 |
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
|
| Jul 27 |
ArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19%
|
| Jul 22 |
Oppenheimer starts ArriVent BioPharma at outperform
|
